Effects of combination therapy with rosuvastatin and fenofibric acid in patients with mixed dyslipidemia and high-sensitivity C-reactive protein (≥2 mg/L)

Journal of Clinical Lipidology

Volumn 5, Issue 5, 2011, Pages 401-407

  Ballantyne, Christie M ^a,b   Davidson, Michael H ^a,b   Setze, Carolyn M ^a,b   Kelly, Maureen T ^a,b  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF CHICAGO   (United States)

Author keywords

C reactive protein; Cardiovascular risk; Dyslipidemia; Fenofibric acid; Rosuvastatin

Indexed keywords

APOLIPOPROTEIN; BIOLOGICAL MARKER; C REACTIVE PROTEIN; FENOFIBRIC ACID; ROSUVASTATIN;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; DYSLIPIDEMIA; FEMALE; HUMAN; LONG TERM CARE; MALE; MONOTHERAPY; POST HOC ANALYSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

ADULT; AGED; C-REACTIVE PROTEIN; CHOLESTEROL, HDL; CHOLESTEROL, LDL; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; DYSLIPIDEMIAS; FEMALE; FENOFIBRATE; FLUOROBENZENES; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; MIDDLE AGED; PYRIMIDINES; RISK; SULFONAMIDES; TRIGLYCERIDES;

EID: 80053892246     PISSN: 19332874     EISSN: 18764789     Source Type: Journal    
DOI: 10.1016/j.jacl.2011.06.010     Document Type: Article

References (14)

1. D.A. Morrow, J.A. de Lemos, and M.S. Sabatine Clinical relevance of C-reactive protein during follow-up of patients with acute coronary syndromes in the Aggrastat-to-Zocor Trial Circulation 114 2006 281 288 (Pubitemid 44297094)
2. P.M. Ridker, D.A. Morrow, and L.M. Rose Relative efficacy of atorvastatin 80 mg and pravastatin 40 mg in achieving the dual goals of low-density lipoprotein cholesterol <70 mg/dl and C-reactive protein <2 mg/l: an analysis of the PROVE-IT TIMI-22 trial J Am Coll Cardiol 45 2005 1644 1648 (Pubitemid 40704500)
3. E.Y. Yang, V. Nambi, and Z. Tang Clinical implications of JUPITER (Justification for the Use of statins in Prevention: an Intervention Trial Evaluating Rosuvastatin) in a U.S. population insights from the ARIC (Atherosclerosis Risk in Communities) study J Am Coll Cardiol 54 2009 2388 2395
4. P.M. Ridker, C.P. Cannon, and D. Morrow C-reactive protein levels and outcomes after statin therapy N Engl J Med 352 2005 20 28 (Pubitemid 40075677)
5. P.M. Ridker, E. Danielson, and F.A. Fonseca Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein N Engl J Med 359 2008 2195 2207
6. K.K. Ray, C.P. Cannon, and R. Cairns Relationship between uncontrolled risk factors and C-reactive protein levels in patients receiving standard or intensive statin therapy for acute coronary syndromes in the PROVE IT-TIMI 22 trial J Am Coll Cardiol 46 2005 1417 1424 (Pubitemid 41446175)
7. P.M. Ridker, E. Danielson, and F.A. Fonseca Reduction in C-reactive protein and LDL cholesterol and cardiovascular event rates after initiation of rosuvastatin: a prospective study of the JUPITER trial Lancet 373 2009 1175 1182
8. P.H. Jones, M.H. Davidson, and M.L. Kashyap Efficacy and safety of ABT-335 (fenofibric acid) in combination with rosuvastatin in patients with mixed dyslipidemia: a phase 3 study Atherosclerosis 204 2009 208 215
9. E.M. Roth, R.S. Rosenson, and D.M. Carlson Efficacy and safety of rosuvastatin 5 mg in combination with fenofibric acid 135 mg in patients with mixed dyslipidemia-a phase 3 study Cardiovasc Drugs Ther 24 2010 421 428
10. H.E. Bays, P.H. Jones, and S.M. Mohiuddin Long-term safety and efficacy of fenofibric acid in combination with statin therapy for the treatment of patients with mixed dyslipidemia J Clin Lipidol 2 2008 426 435 (Pubitemid 352795715)
11. P.H. Jones, H.E. Bays, and M.H. Davidson Evaluation of a new formulation of fenofibric acid, ABT-335, co-administered with statins Clin Drug Investig 28 2008 625 634
12. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report Circulation 106 2002 3143 3421
13. M.S. Kipnes, E.M. Roth, and J.M. Rhyne Year two assessment of fenofibric acid and moderate-dose statin combination: a phase 3, open-label, extension study Clin Drug Investig 30 2010 51 61
14. J.C. Fruchart, F. Sacks, and M.P. Hermans The Residual Risk Reduction Initiative: a call to action to reduce residual vascular risk in patients with dyslipidemia Am J Cardiol 102 2008 1K 34K